242 related articles for article (PubMed ID: 17361995)
1. Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
Greco MN; Hawkins MJ; Powell ET; Almond HR; de Garavilla L; Hall J; Minor LK; Wang Y; Corcoran TW; Di Cera E; Cantwell AM; Savvides SN; Damiano BP; Maryanoff BE
J Med Chem; 2007 Apr; 50(8):1727-30. PubMed ID: 17361995
[TBL] [Abstract][Full Text] [Related]
2. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.
de Garavilla L; Greco MN; Sukumar N; Chen ZW; Pineda AO; Mathews FS; Di Cera E; Giardino EC; Wells GI; Haertlein BJ; Kauffman JA; Corcoran TW; Derian CK; Eckardt AJ; Damiano BP; Andrade-Gordon P; Maryanoff BE
J Biol Chem; 2005 May; 280(18):18001-7. PubMed ID: 15741158
[TBL] [Abstract][Full Text] [Related]
3. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.
Combrink KD; Gülgeze HB; Meanwell NA; Pearce BC; Zulan P; Bisacchi GS; Roberts DG; Stanley P; Seiler SM
J Med Chem; 1998 Nov; 41(24):4854-60. PubMed ID: 9822554
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 4-amino-3,4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds.
Barlow JW; Walsh JJ
Eur J Med Chem; 2008 Dec; 43(12):2891-900. PubMed ID: 18406013
[TBL] [Abstract][Full Text] [Related]
5. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
Leftheris K; Ahmed G; Chan R; Dyckman AJ; Hussain Z; Ho K; Hynes J; Letourneau J; Li W; Lin S; Metzger A; Moriarty KJ; Riviello C; Shimshock Y; Wen J; Wityak J; Wrobleski ST; Wu H; Wu J; Desai M; Gillooly KM; Lin TH; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Zhang R; Diller D; Doweyko A; Sack J; Baldwin J; Barrish J; Dodd J; Henderson I; Kanner S; Schieven GL; Webb M
J Med Chem; 2004 Dec; 47(25):6283-91. PubMed ID: 15566298
[TBL] [Abstract][Full Text] [Related]
6. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
7. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
Grembecka J; Mucha A; Cierpicki T; Kafarski P
J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
[TBL] [Abstract][Full Text] [Related]
8. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
Tully DC; Liu H; Chatterjee AK; Alper PB; Epple R; Williams JA; Roberts MJ; Woodmansee DH; Masick BT; Tumanut C; Li J; Spraggon G; Hornsby M; Chang J; Tuntland T; Hollenbeck T; Gordon P; Harris JL; Karanewsky DS
Bioorg Med Chem Lett; 2006 Oct; 16(19):5112-7. PubMed ID: 16876402
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.
He S; Gaça MD; McEuen AR; Walls AF
J Pharmacol Exp Ther; 1999 Nov; 291(2):517-23. PubMed ID: 10525066
[TBL] [Abstract][Full Text] [Related]
11. Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.
Han Y; Belley M; Bayly CI; Colucci J; Dufresne C; Giroux A; Lau CK; Leblanc Y; McKay D; Therien M; Wilson MC; Skorey K; Chan CC; Scapin G; Kennedy BP
Bioorg Med Chem Lett; 2008 Jun; 18(11):3200-5. PubMed ID: 18477508
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
Terasaka T; Okumura H; Tsuji K; Kato T; Nakanishi I; Kinoshita T; Kato Y; Kuno M; Seki N; Naoe Y; Inoue T; Tanaka K; Nakamura K
J Med Chem; 2004 May; 47(11):2728-31. PubMed ID: 15139750
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
17. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
Barrett DG; Catalano JG; Deaton DN; Long ST; Miller LR; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
Bioorg Med Chem Lett; 2004 May; 14(10):2543-6. PubMed ID: 15109647
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
Zhao H; Serby MD; Xin Z; Szczepankiewicz BG; Liu M; Kosogof C; Liu B; Nelson LT; Johnson EF; Wang S; Pederson T; Gum RJ; Clampit JE; Haasch DL; Abad-Zapatero C; Fry EH; Rondinone C; Trevillyan JM; Sham HL; Liu G
J Med Chem; 2006 Jul; 49(15):4455-8. PubMed ID: 16854050
[TBL] [Abstract][Full Text] [Related]
19. Potency variation of small-molecule chymase inhibitors across species.
Kervinen J; Crysler C; Bayoumy S; Abad MC; Spurlino J; Deckman I; Greco MN; Maryanoff BE; de Garavilla L
Biochem Pharmacol; 2010 Oct; 80(7):1033-41. PubMed ID: 20599788
[TBL] [Abstract][Full Text] [Related]
20. The human mast cell chymase gene (CMA1): mapping to the cathepsin G/granzyme gene cluster and lineage-restricted expression.
Caughey GH; Schaumberg TH; Zerweck EH; Butterfield JH; Hanson RD; Silverman GA; Ley TJ
Genomics; 1993 Mar; 15(3):614-20. PubMed ID: 8468056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
